BRANY (Biomedical Research Alliance of New York) research sites now have the opportunity to improve their patient stipend payments and manage their study budgets with a discount from Greenphire’s ClinCard System.
The ClinCard System is a fully configurable and primarily web-based technology, designed to comply with all applicable regulation and enabling sites and sponsors to deliver subject payments (stipends, travel reimbursements, and other ad-hoc payments) in a controlled and automated manner in compliance with industry regulation and in accordance with the specific requirements of each study.
“BRANY’s partnership with Greenphire is a natural extension of our suite of services to our alliance members,” says BRANY’s Carmela Houston-Henry, Director of Sales and Business Development. “Our members benefit from efficiency in managing their study budgets, and study participants receive expedited stipend payments.”
Recently Montefiore Medical Center, the University Hospital for Albert Einstein College of Medicine became the 100th study site to implement the ClinCard system. Montefiore joins a large and established base of sites and more than 20 sponsors and CROs in realizing the ClinCard’s benefits to the clinical trials process. By automating patient stipend payments, reimbursements, and communication through a web-based portal, Greenphire’s innovative technologies enhance the patient experience and improve patient retention, reduce administration associated with patient payments and communication for both site and sponsor users, and centralize reporting, tracking, and auditing of stipends and reimbursements.
The Biomedical Research Alliance of New York (BRANY) is a national organization providing support services to sponsors and investigators involved in research in a wide variety of therapeutic areas, medical devices, biologic and diagnostic trials. Staffed by multi-disciplinary experts, BRANY is an expedited "end-to-end solution" for clinical trials.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.